|
WO2020198368A1
|
|
Compounds and compositions as modulators of tlr signaling
|
|
EP3810133A1
|
|
Method of treating a condition associated with neurodegeneration using inhibitors of oat3
|
|
KR20200143709A
|
|
Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways
|
|
KR20200142549A
|
|
Morpholine derivatives as inhibitors of VPS34
|
|
KR20200138323A
|
|
Compounds as modulators of TLR2 signaling
|
|
BR112020008727A2
|
|
substituted phenyl sulfonyl phenyl triazoles and uses of these
|
|
EP3493814A1
|
|
Lipid-substituted amino 1,2-and 1,3-diol compounds as modulators of tlr2 dimerization
|
|
WO2017020010A1
|
|
Bis-heteroaryl derivatives as modulators of protein aggregation
|
|
WO2016040780A1
|
|
Aminomethyl- and methyloxy-linked tricyclic compounds as inhibitors of protein aggregation
|
|
KR20160113287A
|
|
Heteroarly amides as inhibitors of protein aggregation
|
|
AU2014271313A1
|
|
Compound suitable for the treatment of synucleopathies
|
|
CA2881472A1
|
|
Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways
|
|
BR112015001096A2
|
|
di and triheteroaryl derivatives as protein aggregation inhibitors
|
|
CN104363903A
|
|
Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
|
|
WO2013134371A1
|
|
Methods and compounds to be used in the treatment of neurodegenerative diseases
|
|
AU2010339841A1
|
|
Compound suitable for the treatment of synucleopathies
|
